ClinicalTrials.gg
CompletedNCT01852604Updated Apr 23, 2015

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

A Phase 2 interventional study of Samatasvir and Simeprevir in Chronic Hepatitis C Virus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing simeprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C, Chronic.

Enrollment
6th of 21
143 · median 93
Started
2013
with 4 others
Phase 2
9 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
2 of 21
Merck Sharp & Dohme LLC

Among the 21 studies testing simeprevir in Hepatitis C, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2013, is one of 9 in phase 2, and was the 9th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 21 studies testing simeprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About simeprevir

Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing simeprevir in Hepatitis C, Chronic as a file.
02

Study summary

Parts A and B of this study are designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir and simeprevir when administered in combination with ribavirin (RBV) for 12 weeks in treatment-naïve, Genotype (GT) 1b, 4 and 6 hepatitic C virus (HCV)-infected participants.

Part C of this study is designed to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of samatasvir, simeprevir, TMC647055 and ritonavir (RTV) when administered in combination with or without RBV for 12 weeks in treatment-naïve or interferon/RBV-treatment relapsed, GT 1a and 1b HCV-infected participants.

Read the detailed description

Part A of this study is randomized and double-blind. Parts B and C are randomized and open-label.

03

Conditions studied

  • Chronic Hepatitis C Virus

Keywords

  • HCV
  • Hepatitis C
  • chronic hepatitis C
  • antiviral
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have Genotype 1a, 1b, 4 or 6 infection.
  • Documented clinical history compatible with chronic hepatitis C
  • HCV treatment-naïve or interferon/RBV-treatment (Part C)
  • Must agree to use an acceptable double method of (one of which must be a barrier method) for at least 6 months after the last dose of study drugs.

Exclusion criteria

Exclusion Criteria:

  • Female participants who are pregnant or breastfeeding.
  • (BMI) > 36 kg/m2.
  • Co-infected with virus or (HIV).
  • History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC.
  • History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency.
  • Has one or more known primary or secondary causes of liver disease, other than
  • History of, or active, acute or chronic, liver or biliary injury due to drugs, toxins, non-HCV viral hepatitis, gallstones or other etiologies
  • Donated blood or had significant blood loss 30 days prior to dosing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV

    Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN) · Other: Samatasvir matching placebo

  • Experimental
    Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV

    Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN) · Other: Samatasvir matching placebo

  • Experimental
    Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV

    Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)

  • Experimental
    Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV

    Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)

  • Experimental
    Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV

    Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)

  • Experimental
    Part B: GT 6 - samatasvir 100/simeprevir/RBV

    Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Biological: Pegylated interferon (Peg-IFN)

  • Experimental
    Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV

    Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Drug: TMC647055 · Drug: Ritonavir (RTV) · Biological: Pegylated interferon (Peg-IFN)

  • Experimental
    Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV

    Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks

    Drug: Samatasvir · Drug: Simeprevir · Drug: Ribavirin (RBV) · Drug: TMC647055 · Drug: Ritonavir (RTV) · Biological: Pegylated interferon (Peg-IFN)

Interventions

  • Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

  • Simeprevir will be supplied as 75 and 150 mg oral capsules.

  • Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

  • TMC647055 will be supplied as 150 mg oral capsules.

  • Ritonavir will be supplied as 80 mg/mL oral solution.

  • Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

  • OtherSamatasvir matching placebo

    Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experienced an adverse event (AE)

    Time frame: Up to approximately 95 weeks

  2. Percentage of participants who experienced a serious adverse event (SAE)

    Time frame: Up to approximately 95 weeks

  3. Percentage of participants who experienced a Grade 1-4 laboratory abnormality

    Time frame: Up to 66 weeks

  4. Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Percentage of participants who experienced rapid virologic response (RVR)

    Time frame: Week 4

  2. Percentage of participants who experienced early virologic response (EVR)

    Time frame: Week 12

  3. Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)

    Time frame: Up to 20 weeks

  4. Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)

    Time frame: Up to 24 weeks

  5. Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)

    Time frame: Up to 36 weeks

  6. Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t

    Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84

  7. Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)

    Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84

  8. Pharmacokinetic Parameter: Trough drug concentration (Ctrough)

    Time frame: Days 1, 4, 7, 10, 14, 21, 28, 42, 56 and 84

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2013
First posted
May 14, 2013
Start
Mar 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Apr 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01852604
Responsible party
Sponsor
First posted
May 14, 2013
Start date
Mar 2013
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Apr 23, 2015

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Samatasvir · Simeprevir · Ribavirin

Start the discussion